544 related articles for article (PubMed ID: 29122777)
1. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Janjigian YY; Sanchez-Vega F; Jonsson P; Chatila WK; Hechtman JF; Ku GY; Riches JC; Tuvy Y; Kundra R; Bouvier N; Vakiani E; Gao J; Heins ZJ; Gross BE; Kelsen DP; Zhang L; Strong VE; Schattner M; Gerdes H; Coit DG; Bains M; Stadler ZK; Rusch VW; Jones DR; Molena D; Shia J; Robson ME; Capanu M; Middha S; Zehir A; Hyman DM; Scaltriti M; Ladanyi M; Rosen N; Ilson DH; Berger MF; Tang L; Taylor BS; Solit DB; Schultz N
Cancer Discov; 2018 Jan; 8(1):49-58. PubMed ID: 29122777
[TBL] [Abstract][Full Text] [Related]
2.
Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
[TBL] [Abstract][Full Text] [Related]
3. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Maron SB; Chatila W; Walch H; Chou JF; Ceglia N; Ptashkin R; Do RKG; Paroder V; Pandit-Taskar N; Lewis JS; Biachi De Castria T; Sabwa S; Socolow F; Feder L; Thomas J; Schulze I; Kim K; Elzein A; Bojilova V; Zatzman M; Bhanot U; Nagy RJ; Lee J; Simmons M; Segal M; Ku GY; Ilson DH; Capanu M; Hechtman JF; Merghoub T; Shah S; Schultz N; Solit DB; Janjigian YY
Clin Cancer Res; 2023 Sep; 29(18):3633-3640. PubMed ID: 37406106
[TBL] [Abstract][Full Text] [Related]
4. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Pectasides E; Stachler MD; Derks S; Liu Y; Maron S; Islam M; Alpert L; Kwak H; Kindler H; Polite B; Sharma MR; Allen K; O'Day E; Lomnicki S; Maranto M; Kanteti R; Fitzpatrick C; Weber C; Setia N; Xiao SY; Hart J; Nagy RJ; Kim KM; Choi MG; Min BH; Nason KS; O'Keefe L; Watanabe M; Baba H; Lanman R; Agoston AT; Oh DJ; Dunford A; Thorner AR; Ducar MD; Wollison BM; Coleman HA; Ji Y; Posner MC; Roggin K; Turaga K; Chang P; Hogarth K; Siddiqui U; Gelrud A; Ha G; Freeman SS; Rhoades J; Reed S; Gydush G; Rotem D; Davison J; Imamura Y; Adalsteinsson V; Lee J; Bass AJ; Catenacci DV
Cancer Discov; 2018 Jan; 8(1):37-48. PubMed ID: 28978556
[TBL] [Abstract][Full Text] [Related]
5. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
7.
Klempner SJ; Madison R; Pujara V; Ross JS; Miller VA; Ali SM; Schrock AB; Kim ST; Maron SB; Dayyani F; Catenacci DVT; Lee J; Chao J
Oncologist; 2019 Nov; 24(11):1462-1468. PubMed ID: 31249137
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Esophageal and Gastric Cancer.
Kelly RJ
Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
[TBL] [Abstract][Full Text] [Related]
10.
Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
[TBL] [Abstract][Full Text] [Related]
11. What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
De Mello RA; Castelo-Branco L; Castelo-Branco P; Pozza DH; Vermeulen L; Palacio S; Salzberg M; Lockhart AC
Am Soc Clin Oncol Educ Book; 2018 May; 38():249-261. PubMed ID: 30231398
[TBL] [Abstract][Full Text] [Related]
12. Real-world association of HER2/
Stein SM; Snider J; Ali SM; Miksad RA; Alexander BM; Castellanos E; Schrock AB; Madison R; Swaminathan A; Venstrom JM; McCusker M
Future Oncol; 2021 Nov; 17(31):4101-4114. PubMed ID: 34463133
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
[TBL] [Abstract][Full Text] [Related]
14. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
[TBL] [Abstract][Full Text] [Related]
15. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
16. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
17. Association of
Hino K; Nishina T; Kajiwara T; Bando H; Nakamura M; Kadowaki S; Minashi K; Yuki S; Ohta T; Hara H; Mizukami T; Moriwaki T; Ohtsubo K; Komoda M; Mitani S; Nagashima F; Kato K; Yamada T; Hasegawa H; Yamazaki K; Yoshino T; Hyodo I
JCO Precis Oncol; 2022 Aug; 6():e2200135. PubMed ID: 35952320
[TBL] [Abstract][Full Text] [Related]
18. Where to Start and What to Do Next: The Sequencing of Treatments in Metastatic Esophagogastric Cancer.
Mamdani H; Jalal SI
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-16. PubMed ID: 33770461
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
[No Abstract] [Full Text] [Related]
[Next] [New Search]
